Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma

Summary

This study will use the drug daratumumab in patients who did not achieve at least a very good partial response (VGPR) and are already planned to have an Autologous Stem Cell Transplant (ASCT). Daratumumab will be given before the stem cell collection to attempt to get rid of any multiple myeloma cells that may be present in the stem cell collection and after the ASCT to get rid of any multiple myeloma cells that may be remaining.

Timeline

Start

2021-07-02

Primary completion

2027-01

Completion

2027-01

Outcome

Outcome not reported

Stopped (Enrollment): “Difficult enrollment due to changes in standard of care”

Drugs

Indications